Arax Advisory Partners’s MacroGenics MGNX Stock Holding History

Arax Advisory Partners’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-55	Closed	-$89	–	4125
2025 Q4	$89	Buy	55 +46	+511%	+$72	﹤0.01%	3847
2025 Q3	$15	Buy	+9	New	+$15	﹤0.01%	3584

Other funds holding MGNX

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Arax Advisory Partners's MGNX Position: Q1 2026 in Review

Arax Advisory Partners sold out of MacroGenics (MGNX) in Q1 2026, closing a stake of 55 shares — an estimated $89 sold.

Arax Advisory Partners first reported a position in MGNX in Q3 2025 and held it in 2 quarters. The position peaked at $89 in Q4 2025. 109 funds tracked by Wall St. Rank hold MGNX as of Q1 2026.

Arax Advisory Partners reported no remaining MacroGenics position as of Q1 2026 after selling out during the quarter.
Arax Advisory Partners sold 55 MacroGenics shares in Q1 2026, an estimated $89.
Arax Advisory Partners first reported a position in MacroGenics in Q3 2025 and held it in 2 quarters.
Arax Advisory Partners's MacroGenics position peaked at $89 in Q4 2025.
109 funds tracked by Wall St. Rank held MacroGenics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.